

Charles D Burger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4701060/publications.pdf>

Version: 2024-02-01

65
papers

1,936
citations

304743

22
h-index

265206

42
g-index

66
all docs

66
docs citations

66
times ranked

2554
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2019, 156, 323-337.	0.8	408
2	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	10.7	122
3	An Alternative Echocardiographic Method to Estimate Mean Pulmonary Artery Pressure: Diagnostic and Clinical Implications. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 814-819.	2.8	90
4	Pulmonary Hypertension and Thyroid Disease. <i>Chest</i> , 2007, 132, 793-797.	0.8	89
5	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. <i>Mayo Clinic Proceedings</i> , 2019, 94, 309-325.	3.0	78
6	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2382-2394.	3.0	77
7	Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL Registry. <i>Chest</i> , 2014, 146, 1263-1273.	0.8	74
8	Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease. <i>Biology of Sex Differences</i> , 2018, 9, 15.	4.1	60
9	Accuracy and Precision of Three Echocardiographic Methods for Estimating Mean Pulmonary Artery Pressure. <i>Chest</i> , 2011, 139, 347-352.	0.8	55
10	Comparison of Body Habitus in Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management With Normative Values From the National Health and Nutrition Examination Survey. <i>Mayo Clinic Proceedings</i> , 2011, 86, 105-112.	3.0	51
11	Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 237-246.	10.7	50
12	A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1576-1582.	3.2	47
13	Pulmonary Mechanics in Lymphangiomyomatosis. <i>The American Review of Respiratory Disease</i> , 1991, 143, 1030-1033.	2.9	45
14	Accuracy of chest high-resolution computed tomography in diagnosing diffuse cystic lung diseases. <i>European Respiratory Journal</i> , 2015, 46, 1196-1199.	6.7	35
15	Pulmonary Hypertension in COPD: A Review and Consideration of the Role of Arterial Vasodilators. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 137-144.	1.6	34
16	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 834-842.	0.9	31
17	Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 464-472.	0.6	27
18	Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 613-622.	3.2	27

#	ARTICLE	IF	CITATIONS
19	Pulmonary arterial stiffness assessed by cardiovascular magnetic resonance imaging is a predictor of mild pulmonary arterial hypertension. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1881-1892.	1.5	26
20	The Significance of Pulmonary Artery Size in Pulmonary Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2014, 2, 243-259.	2.5	25
21	Prevalence of metabolic syndrome in patients with pulmonary hypertension. <i>Clinical Respiratory Journal</i> , 2017, 11, 721-726.	1.6	25
22	United States Pulmonary Hypertension Scientific Registry. <i>Chest</i> , 2021, 159, 311-327.	0.8	25
23	A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 919-928.	3.2	24
24	Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension. <i>Transplantation</i> , 2021, 105, 2283-2290.	1.0	24
25	Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 731-739.	1.9	23
26	Medical treatment update on pulmonary arterial hypertension. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 264-272.	2.5	22
27	Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis. <i>Respiratory Medicine</i> , 2015, 109, 1354-1359.	2.9	22
28	Cardiopulmonary exercise testing in patients with pulmonary hypertension: clinical recommendations based on a review of the evidence. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 279-295.	2.5	22
29	The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. <i>Pulmonary Circulation</i> , 2017, 7, 82-88.	1.7	20
30	Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 33.	2.5	20
31	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. <i>Mayo Clinic Proceedings</i> , 2021, 96, 601-618.	3.0	20
32	Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 22.	2.5	19
33	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	1.7	17
34	The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. <i>Respirology</i> , 2005, 10, 643-648.	2.3	16
35	In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis. <i>Human Pathology</i> , 2018, 79, 199-207.	2.0	15
36	Conversion From Sildenafil to Tadalafil. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 550-557.	2.0	14

#	ARTICLE	IF	CITATIONS
37	Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 291-302.	0.9	14
38	Digital Health Surveillance Strategies for Management of Coronavirus Disease 2019. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 109-117.	2.4	13
39	High-risk echocardiographic features predict mortality in pulmonary arterial hypertension. <i>American Heart Journal</i> , 2017, 189, 167-176.	2.7	12
40	Multidisciplinary Perioperative Management of Pulmonary Arterial Hypertension in Patients Undergoing Noncardiac Surgery. <i>Southern Medical Journal</i> , 2018, 111, 64-73.	0.7	12
41	Pulmonary Arterial Hypertension in a Patient with β -Thalassemia Intermedia and Reversal with Infusion Epoprostenol Then Transition to Oral Calcium Channel Blocker Therapy: Review of Literature. <i>Pulmonary Circulation</i> , 2014, 4, 520-526.	1.7	11
42	Mosaic Pattern of Lung Attenuation on Chest CT in Patients with Pulmonary Hypertension. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 205-212.	2.5	9
43	Research Response to SARS-CoV-2/COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, S52-S55.	3.0	8
44	Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity. <i>Clinical Respiratory Journal</i> , 2014, 8, 404-409.	1.6	6
45	Topic-Based, Recent Literature Review on Pulmonary Hypertension. <i>Mayo Clinic Proceedings</i> , 2021, 96, 3109-3121.	3.0	6
46	Screening for Connective Tissue Disease in Pulmonary Arterial Hypertension. <i>Southern Medical Journal</i> , 2014, 107, 666-669.	0.7	6
47	Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer. <i>Southern Medical Journal</i> , 2021, 114, 607-613.	0.7	5
48	Facemasks and Walk Distance in Pulmonary Arterial Hypertension Patients. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 835-838.	2.4	5
49	What Can be Learned in 6 Minutes? 6-Minute Walk Test Primer and Role in Pulmonary Arterial Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2010, 9, 107-111.	0.1	5
50	Low-dose sirolimus in retroperitoneal lymphangiomyomas. <i>Lung India</i> , 2019, 36, 349.	0.7	5
51	Comparing Diagnosis and Treatment of Pulmonary Hypertension Patients at a Pulmonary Hypertension Center versus Community Centers. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 5.	2.5	5
52	The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management. <i>American Journal of Managed Care</i> , 2016, 22, S3-15.	1.1	5
53	Should All Patients with Pulmonary Hypertension Undergo HIV Serologic Testing?. <i>Southern Medical Journal</i> , 2011, 104, 589-592.	0.7	4
54	Pulmonary Arterial Hypertension and Obesity. <i>The Open Obesity Journal</i> , 2010, 2, 132-136.	0.1	4

#	ARTICLE	IF	CITATIONS
55	Prognostication in Pulmonary Arterial Hypertension with Submaximal Exercise Testing. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 15-23.	2.5	3
56	Prevalence of Sodium and Fluid Restriction Recommendations for Patients with Pulmonary Hypertension. <i>Healthcare (Switzerland)</i> , 2015, 3, 630-636.	2.0	3
57	Two cases of stem cell therapy for pulmonary hypertension: A clinical report. <i>Respiratory Medicine CME</i> , 2011, 4, 70-74.	0.1	2
58	Thyroid disease in pulmonary hypertension: Strange bedfellows?. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1414-1415.	0.6	2
59	Perioperative Evaluation and Management of Patients With Portopulmonary Hypertension Aiming for Orthotopic Liver Transplantation. <i>Advances in Pulmonary Hypertension</i> , 2013, 12, 68-74.	0.1	2
60	Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension?. <i>Oman Medical Journal</i> , 2016, 31, 345-351.	1.0	2
61	S-LAM in Men: Is Pulmonary Function Different from That Seen in Women?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 356-356.	5.6	1
62	Twelve-Year Survival in a Patient With Systemic Sclerosisâ€‘Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 376-379.	2.4	1
63	Variability in the Prevalence of Acute Bronchoresponsiveness in Different Populations of Patients With Lymphangioleiomyomatosis. <i>Chest</i> , 2008, 134, 217.	0.8	0
64	The Vasoreactive Patient: Diagnosis, Treatment, and Follow-up. <i>Advances in Pulmonary Hypertension</i> , 2007, 6, 176-179.	0.1	0
65	Remote 6-minute Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 0, , .	5.6	0